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creating one category for all cerebrovascular disease presentations and thus accelerate identification
of targets for dementia prevention.
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Fig. 1. Approaches to tackling vascular factors in neurodegenerative dis-
ease. The challenge is to integrate the different clinical presentations
when attempting to recognize more completely the interactions between
vascular disease and neurodegeneration and thence improve prevention
and treatment.1. Introduction
Worldwide, nearly 36 million people are estimated to be
living with dementia. This is expected to triple by 2050. Ce-
rebrovascular disease causes up to 45% of all dementias
alone or in conjunction with Alzheimer’s disease (AD)
[1,2]. Despite vascular risk factor reduction being an
achievable target for public health intervention in many
countries, and some recent evidence of success in
preventing dementia [3], knowledge about vascular contri-
butions to dementia remains modest.
Many studies, from the early 1990s onward [4], have
demonstrated that cognitive impairment and dementia are
both common and under-recognized after stroke [5]. The
concept of “vascular cognitive impairment” was introduced
in 1994 [6], covering a spectrum of cognitive impairment af-
ter stroke to cognitive impairment in association with other-
wise asymptomatic cerebrovascular disease. The most
common vascular contributor to dementia is cerebral small
vessel disease (SVD) [7], a condition that affects perforating
vessels, thence white and gray matter, and accelerates neuro-
degenerative processes. Vascular dementia reflects the
global effects of vascular disease on the brain, not just of
multiple individual infarcts. [8,9] It results in stroke,
cognitive decline and dementia, plus neuropsychiatric
symptoms, gait, balance [8,9], and continence problems
[10], necessitating a larger framework for targeted, compre-
hensive studies [11].
In 2006, the National Institute for Neurological Disorders
and Stroke and the Canadian Stroke Network convened a
multidisciplinary research group to recommend standards
for the study of vascular cognitive impairment [11]. In
2013 the Alzheimer’s Association convened an expert work-
ing group, which summarized the state of vascular cognitive
impairment science and identified areas where new knowl-
edge is needed [12]. However, despite strong and unanimous
evidence for the major burden of vascular cognitive impair-
ment on both patients and their caregivers [13], most demen-
tia research largely overlooks vascular disease as a cause. In
part, this reflects that clinicians and researchers working on
dementia, stroke, physical, or psychiatric manifestations are
still too often segregated. “Stroke” and “dementia” (both
syndromes, not pathological diagnoses) present to different
clinical specialists (Fig. 1); stroke specialists under-
recognize the cognitive impact of stroke, whereas dementia
specialists under-recognize vascular inputs to dementia
pathophysiology. This separation also affects research andfunding initiatives, for example, vascular disease was rarely
mentioned in a report on 169 European studies considered
relevant to neurodegenerative disease research [14]. Better
diagnostic criteria for the different cognitive profiles of
vascular and AD are also needed [15].
The recognition of an important role for cerebrovascular
disease in dementia opens major therapeutic opportunities.
Vascular risk factor reduction and stroke prevention may
already be reducing dementia incidence [3,16]. Increased
government and public concern about dementia, as well as
better grouping of codes for different cerebrovascular
disease presentations in the revised International
Classification of Disease (ICD) codes version 11 (ICD-11,
release 2018, http://www.who.int/classifications/icd/
revision/en/), will help advance understanding of
cerebrovascular disease and its impact on neurodegeneration.
Here, we report on an initiative funded by the JPND to
promote efficient use of available data in which we identified
information, relevant to vascular disease, available in
different types of studies that could provide large, statisti-
cally robust, generalizable data sets, and create platforms
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trials [17]. We used the exemplar survey data to identify ma-
jor gaps in knowledge, methodological issues and suggest
priority actions to advance the field.2. Method
We convened a group of experts in stroke and cerebrovas-
cular disease, AD, epidemiology, psychology, neuroimaging,
and clinical trials (Appendix). We designed a survey aiming
to capture information about data available in cohorts relevant
to vascular contributions to neurodegeneration. A “relevant
cohort” could comprise patients with stroke/transient ischae-
mic attack (TIA), or suspected cognitive impairment or de-
mentia, or healthy subjects, from a hospital or geographical
population, and would have information on vascular disease
and/or risk factors, and one or more of the following: cogni-
tive data, long-term outcomes (including physical function
and mood), neuroimaging including biomarkers of vascular
disease and/or neurodegeneration, physiological measures
(e.g., blood pressure, vascular stiffness), or biomarker sam-
ples with a relevant vascular link. The study could be
completed or ongoing, cross-sectional or longitudinal, obser-
vational, or a clinical trial. Theminimum sample for inclusion
was 50 participants, with no age or geographical limits.
The survey (Supplementary Material), designed for online
delivery, sought information on whether participants were
healthy or recruited from a stroke or memory or other relevant
clinic or participated in a clinical trial. Data were collected on
demographics, medical history, risk factors, cognition, brain
imaging, physiological measures, comorbidities at inclusion,
duration and frequency of follow-up, follow-up assessments,
outcome events, whether the studywas completed or ongoing,
availability of bio- or genetic samples for further analysis, in-
terest of investigators in data sharing, and whether approvals
for sharing were already in place.
The survey was piloted by three members of the expert
group (JMW, MD, and ES), before being distributed widely.
It ran from November 15, 2014 until August 31, 2015 with
updates for ongoing studies to November 2015. We initially
invited participation from investigators of studies in Europe
through the JPND Vascular Disease group, relevant studies
listed in the JPND report [14], networks, and studies known
to them, for example, Dementia Platform UK, the German
Center for Neurodegenerative Diseases (DZNE), and “Con-
stances” in France; however, investigators based in North
America, Australasia, and the Asia Pacific Region also ex-
pressed interest and were included. We recognized that the
survey was unlikely to capture all studies but aimed to cap-
ture a broad sample, particularly from the vascular disease
perspective (including clinical trials), as these are under-
represented in other dementia initiatives [14,18–20].
We performed descriptive statistics and meta-analyses
(random effects methods) [21]. For detailed analyses of
cognition in relation to stroke, we used studies that collected
data on stroke and cognition from subjects without prestrokedementia in community-based studies or in subjects with
stroke (hospital-based post-stroke cognitive impairment co-
horts). Responses were received from 68 investigators (some
provided data on several studies). Samples were updated to
include ongoing recruitment to December 01, 2015. Five
incomplete responses were removed from further analysis
(for full details, see Supplementary Material).
Fifty-five experts (Appendix) discussed the data to identify
knowledge gaps requiring new data, implications of ICD-11
disease codes (http://www.who.int/classifications/icd/revision/
en/), agree early targets for shared data analysis, and plan
future analyses of existing data and new research initiatives.3. Results
The survey collected data on a total of 96 studies, including
167,064 participants, or 667,064 with UK Biobank [22]
(186,000 and 686,000, respectively including target samples
in ongoing studies; Table 1; Supplementary Table 1). The
sample size ranged from 41 to 29,852 (excluding UK Bio-
bank). The mean age was 72, range 15 to 106 years. There
were 84 observational studies (11 cross sectional and 73 lon-
gitudinal) and12 randomized clinical trials. Themain types of
studies overlapped (some recruited from several sources by
various methods, Table 2) but, in general, most studies could
be attributed to the following categories: community-based
cohorts including population studies (32 studies, of which
28 were suitable for analyzing incident post-stroke dementia,
sample size.600,000 subjects), hospital-based stroke clinics
(i.e., stroke and TIA services, 26 studies, 12 suitable for
analyzing incident post-stroke dementia, w4700 subjects),
hospital-based memory clinics (15 studies, w20,000 sub-
jects), and randomized clinical trials (12 trials,w20,000 sub-
jects); 38 studies were ongoing (recruiting or long-term
follow-up, Table 2). Some studies recruiting frommixed sour-
ces (Table 2, Supplementary Table 1) were not included in
detailed analysis in the following section (or in Table 1), yet
provide other relevant information (details in
Supplementary Material). The longest duration of follow-up
so far was more than 5 years (Fig. 2). Sixty-seven studies
were based in Europe, 17 in North America, and 12 in the
Asia Pacific Region (excluding 2 incomplete entries).
Most cohorts (w86/96) did neither appear in the JPND
report of 169 cohort studies [14] nor overlap by more than
20% with other recent initiatives, for example, Cohort
Studies of Memory in an International Consortium
(COSMIC) [18], Virtual International Stroke Trials Archive
(VISTA) Cognition [22], or the Consortium of Studies of
Post-Stroke Cognitive Decline and Dementia (STROKOG;
[23]). This lack of overlap indicates a gap in information
about vascular disease in neurodegeneration when viewed
from “traditional” neurodegenerative perspectives and shows
that there is a large amount of data available for sharing and
meta-analyses if it could be brought together efficiently and
effectively.
Table 1
Summary of types and amount of data available in cohorts recorded in the survey that were analyzed in detail
Community-based
cohorts
Hospital-based
cohorts from
stroke services
Hospital-based cohorts
from memory clinics Clinical trials All
Number of studies
Total/completed recruitment/
completed follow-up
28/22/15 12/8/5 16/8/4 12/7/5 68/45/29
Current number of patients
Total/with imaging* 583.851/23.388 4.134/3.529 19.144/5.982 20.035/12.050 627.164/44.949
Planned sample size
Total/with imaging data .600.000/.150.000 4.702/4.289 21.353/8.153 22.314/12.439 w655.000/w172.000
Mean age (y) 71 70 73 71.6 72
Male sex (%) 46 56 51 58.5 46
Number of studies with
Clinical diagnosis of stroke supported
by neuroimaging
MRI/CT/MRI or CT 6/1/4 5/4/3 4/0/2 3/2/6 18/7/15
Baseline information on risk factors
Hypertension/diabetes mellitus/
hypercholesterolemia/smoking/
medication/education
26/26/22/26/27/27 12/12/12/12/12/11 16/16/16/16/15/16 10/10/10/9/8/4 64/64/60/63/62/58
Follow-up assessment
After months 3/6/12/24/36/48/60 1/2/6/10/10/5/6 9/6/9/3/6/3/6 0/4/14/9/7/1/0 7/4/5/2/2/0/0 17/16/34/24/25/9/12
Functional outcomes
mRS/BI/SIS/EuroQol/SF36/ADL or
IADL
3/2/0/1/2/5 7/7/1/2/2/2 4/4/1/3/0/4 8/3/1/7/1/0 22/16/3/13/5/11
Vascular outcomes
Stroke/TIA/MI/Vascular death 17/14/16/15 10/7/7/8 14/12/10/9 9/8/9/7 50/41/42/39
Cognitive outcomes
MCI/Dementia/MoCA or ACE-R/
MMSE/TICS/Memory/Executive/
Reaction time/Visuospatial
7/15/4/17/16/18/15/16 7/9/7/10/8/7/4/7 8/11/6/12/14/14/10/14 1/2/1/8/6/4/4/4/4 23/37/18/47/44/43/33/41
Psychiatric outcomes
Depression/anxiety 18/12 9/7 14/7 7/0 48/26
Mobility outcomes
Gait/balance/manual dexterity 1/0/0 1/0/0 1/0/0 0/0/0 3/0/0
Criteria used for a diagnosis of MCI
DSM-V/AHA or ASA/Petersen/
NIA-AA/other
1/1/4/3/2 2/1/3/0/1 0/2/2/6/3 0/0/0/0/6 3/4/9/9/12
Criteria used for a diagnosis of
dementia
DSM-IV/DSM-V/ICD-10/other 7/3/3/3 5/1/1/0 10/0/0/3 1/0/0/6 23/4/4/12
Criteria used for diagnosis of
vascular CI
NINDS-AIREN/AHA or ASA/other 8/4/2 1/1/1 7/4/1 0/0/0 16/9/4
Criteria used for a diagnosis of AD
NIA-AA clinical/DSM-V/DSM-V/
NINCDS-ADRDA/other
5/5/0/2/6 1/4/1/0/0 8/2/1/4/2 0/0/0/0/0 14/11/2/6/8
Stored sample
DNA/blood 26/20 7/6 13/14 3/3 49/43
Abbreviations: ACE-R, revised Addenbrooke’s cognitive examination; AD, Alzheimer’s disease; AHA, American Heart Association; AIREN, Association
Internationale pour la Recherche et l’Enseignement en Neurosciences; ASA, American Stroke Association; CT, computed tomography; DSM, Diagnostic and
StatisticalManual of Mental Disorders; ICD, International Classification of Disease; MoCA,Montreal Cognitive Assessment;MCI, mild cognitive impairment;
MI, myocardial infarction; MMSE, mini-mental state examination; MRI, magnetic resonance imaging; NIA-AA, National Institutes of Aging–Alzheimer’s As-
sociation; NINDS, National Institute for Neurological Disorders and Stroke; TIA, transient ischaemic attack; TICS, Telephone Interview of Cognitive Assess-
ment.
NOTE. For studies not included in detailed analysis and full details of all studies, see Supplementary Table 1.
*Number includes UKBiobank of 500,000 recruited, 100,000 expected to have brain and other imaging. For 11 cross-sectional and 17 longitudinal studies not
listed in Table 1, see Supplementary Material.
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Table 2
Summary of 84 observational cohort studies by study setting
Setting n
Observational studies 84
Cross sectional 11
Longitudinal 73
Community based 32
Via advertising 9
Population based 23
Hospital based for some recruits and community based for others 4
Stroke or TIA clinic 1
Stroke or TIA clinic and memory clinic 1
Memory clinic and general geriatric clinic 1
Other 1
Hospital/clinical based 37
Stroke or TIA clinic 19
Stroke or TIA clinic and memory clinic 2
Stroke or TIA clinic and memory clinic and general geriatric
clinic
3
Stroke or TIA clinic and memory clinic and general geriatric
clinic and any healthy volunteers
1
Stroke or TIA clinic and memory clinic and any healthy
volunteers
1
Memory clinic 5
Memory clinic and general geriatric clinic 1
Other 5
Abbreviation: TIA, transient ischaemic attack
NOTE. Of 84 observational studies, 11 are cross sectional, and 73 are lon-
gitudinal. Data on 12 clinical trials are not included.
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Community-based (including population-based) cohorts
are the best way to determine the relative contribution of
vascular and other pathologies to the development of demen-
tia and cognitive aging. They permit assessment of risk fac-
tor levels before the development of cognitive impairment or
dementia, and hence, risk factor measurement is less likely
to be affected by disease or its treatment. These cohorts often
have repeated measures, starting in midlife, so, the impact of
cumulative exposures, including during specific ages, can be
explored. In contrast, clinical studies usually recruit from
one extreme of the population distribution of vascular sus-
ceptibility; these studies may generate hypotheses that can
be tested in population-based cohorts.
We gathered data from a representative sample of 32
community-based cohorts (Supplementary Table 1,
Supplementary Fig. 1; 28 suitable for analysis) that defined
the extent of vascular compromise, and structural brain
injury in each person using serial brain imaging, and also
measured global and domain-specific cognitive perfor-
mance, mood, and physical function. Most studies prospec-
tively followed their participants using health record
linkage, questionnaires, or repeated examinations, to detect
progression to cognitive impairment, stroke, or dementia.
Most studies include biobanking, and a few have prospective
postmortem brain banks. The community-based studieswere either geographically population-based or recruited
through advertisement and other strategies.
Most studies were conducted in the past three decades in
North America and Europe, studied older participants (mean
age 70 years), and used brain magnetic resonance imaging
(MRI). Sample size ranged from around 100 to 500,000 par-
ticipants (median: 1400; Q1–Q3: 400–9500), with imaging
planned for w150,000. However, there are limitations. The
imaging protocols, hence sensitivity to vascular pathology,
varied, particularly in the older studies. Vascular risk factor
assessment covered common risk factors, but interim TIA,
clinical stroke, and stroke subtype were ascertained with
varying degrees of rigor ranging from surveillance for inci-
dent events with direct participant examination and
consensus review by study investigators, through medical re-
cords linkage, to self-reported events. Data on lipids, inflam-
matory markers, and renal function were missing from about
half the studies. There was considerable variation in methods
and timing used to assess vascular and cognitive outcomes.
Data from a wider age span starting in youth to mid adult-
hood, diverse race, ethnic, and geographic origins, but using
common protocols for cognition, physical function, mini-
mum standard physiological measures, andMRI, are needed.
3.1.2. Post-stroke cognitive impairment cohorts
In hospital-based series, about 20% of stroke patients
have dementia after stroke, and the cumulative incidence
of dementia after the first year is about 3% pa [24]. The sur-
vey identified 26 hospital-based cohorts recruiting from
stroke/TIA6 other services (Table 2). Twelve had data suit-
able for analysis comprising studies that recruited patients
presenting to hospital with ischemic stroke or TIA, followed
longitudinally with cognitive and other measures. These
studies collectively included .4134 subjects currently
(planned .4700), and nearly 90% have structural neuroi-
maging. Most assessed educational attainment (although
few assessed premorbid intelligence quotient), most used
the Montreal Cognitive Assessment (MoCA) and all
collected details of vascular disease and vascular risk factors
(Supplementary Fig. 2). Of note, several cohorts include
amyloid-positron emission tomography imaging, thus
enabling assessment of the interactions between vascular
and amyloid pathology in cognitive decline.
These data, if combined, would help overcome many
gaps in knowledge remaining from previous post-stroke
cognitive impairment studies [5,25]: poor generalizability
due to small sample and inclusion of high-functioning
ischemic, nondysphasic, stroke patients, with an informant;
or various entry restrictions, for example, inclusion of TIAs
only, or first-only strokes, rather than any stroke. The variety
of cognitive, physical, and physiological assessment tools
and lack of prestroke cognition or contemporaneous mood
data restrict comparisons. There is little information on
concomitant AD pathology, or on biomarkers of vascular de-
mentia, or pathology specimens to determine true propor-
tions of vascular disease, and imaging acquisitions vary.
Fig. 2. Duration of follow-up by study type and available information. Note some community-based studies have .5 years of follow-up.
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studies would increase research efficiency.
3.1.3. Memory clinics
Patients attending a memory clinic represent a highly
relevant population to study vascular contributions to cogni-
tive decline and dementia. Most patients attending memory
clinics have vascular lesions co-occurring with other pathol-
ogies, in particular, Alzheimer-type processes. However,
there is limited evidence from longitudinal studies and ran-
domized controlled trials (RCTs) in memory clinic-based
cohorts to determine how much the vascular lesions
contribute to cognitive profiles, predict prognosis, or should
influence treatment. Extrapolation of observations from, for
example, population-based studies, may not be valid because
disease predictive factors in a relatively healthy populationmay not necessarily predict disease progression among indi-
viduals affected by the disease, or vice versa.
We identified 15 cohorts that included memory clinic pa-
tients (Table 2, Supplementary Fig. 3), some providing data
only on memory [26], whereas others included other clinical
presentations [27]. Cohort sizes were generally modest, with
8 of 15 cohorts including 200 patients, although baseline
data are available on 19,144 patients of mean age of 73 years.
All studies collected data on demographics, risk factors for
vascular disease including education. Cognitive test results
and neuroimaging (mostly MRI or computed tomography)
were available from most patients in all cohorts. However,
diagnostic criteria for mild cognitive impairment (MCI)
and dementia, and its subtypes, varied across cohorts. More-
over, althoughmost of the studies collected longitudinal data,
both timing and content of follow-up varied substantially.
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such as the extent to which different pathologies may have
differential prognostic impact in different stages of the de-
mentia process. For example, larger studies at different dis-
ease stages across multiple clinics would help to determine if
white matter hyperintensity (WMH) burden is indeed a
stronger predictor of progressive brain atrophy in people
with MCI and early AD than in later stages [28,29].
Further studies are needed to determine how much co-
occurring pathologies affect risk-benefit ratios of treatments
that are typically used to reduce vascular risk, such as antith-
rombotic drugs. For example, randomized trials of aspirin in
patients with AD observed rates of intracerebral hemorrhage
that were much higher than those in people without AD [30].
3.1.4. Physical function
Gait and balance disorders are common in elderly people,
increasing rapidly from around 15% at the age of 60 years to
.50% at age of 80 years [31–33]. They are often
multifactorial and increase falls, institutionalization, and
mortality [31,32,34]. For example, Parkinson’s disease,
impairs gait, and balance [35], but vascular cerebral disor-
ders also disturb gait and may contribute to Parkinsonian
symptoms [36,37], particularly in SVD where gait is the
second commonest symptom after cognitive disturbance
[38,39]. The Leukoaraiosis and Disability in the Elderly
Study (LADIS) showed that gait and balance were
correlated with WMH severity [8]. As gait represents a com-
plex higher order form of motor functioning, impaired gait
and cognition are closely intertwined [31].
However, gait and balance were rarely assessed in
population-based or hospital-based post-stroke or memory
studies. The survey found very limited information, but
such details were poorly captured in the questionnaire. For
example, none of five studies from general geriatric clinics
mentioned recording gait, walking, or movement. Under
“other,” no study mentioned these words either. Seven other
studies mentioned “gait” (Supplementary Table 1,
ABC1936, ABC1921, CASPER, ONDRI, PURE-MIND,
RUN DMC, STRIDE) although we recognize that some
studies that did not specifically mention gait do collect
such data. This suggests that problems of gait and balance
are under-recognized compared with other features of
vascular neurodegeneration and hence are poorly assessed
in vascular-focused clinics for older people, despite repre-
senting a major problem for older people, their families, hos-
pitals, and social services.
3.1.5. Clinical trials
Many acute stroke and stroke prevention RCTs have not
collected cognitive data because of the following: (1) they
focused on the physical consequences of stroke; (2) cogni-
tive testing was considered too laborious and not applicable
to participants whose vision, speech, or hand function were
impaired; or (3) there was no informant, thus excluding sig-
nificant proportions of patients from testing [40].The survey collected data from 12 RCTs, testing treat-
ments for acute ischemic or hemorrhagic stroke or secondary
prevention of ischemic stroke (Supplementary Table 1). The
sample size ranged from 41 to 4750, total current sample
20,035 (planned sample 22,314), of which 12,439 will
have detailed neuroimaging. The mean participant age is
71.6 years, and 58.5% are men. Most trials consistently re-
corded baseline vascular risk factors including blood pres-
sure, and outcomes such as recurrent vascular events and
functional outcome assessed using the modified Rankin
Scale. However, cognitive tests varied (eight used the
mini-mental state examination [MMSE], one the MoCA,
five the Telephone Interview of Cognitive Assessment
(TICS), and two a more detailed assessment), none tested
premorbid intelligence quotient although four trials recorded
educational attainment, few assessed mood, and none
corrected for imaging features such as WMH burden (a pre-
dictor of post-stroke cognitive impairment). The latest
follow-up was at 12months in all but two trials (latest assess-
ment 24 and 36 months in one trial each), substantially
shorter than that in the other study types (Fig. 2).
An individual patient data meta-analysis of cognition af-
ter stroke in these trials, which are typical of many stroke
treatment or prevention trials, would be hampered by lack
of consistency in cognitive measures and of long-term
data, despite providing exemplary vascular risk factor and
vascular outcome assessments. Inadequate attention has
been given to assessing cognition after stroke in RCTs to
date. Agreement on pragmatic and rapid ways to assess
important cognitive domains such as executive function
and processing speed, not just memory, and to correct for
premorbid cognition, depression, and WMH burden on im-
aging, are essential to advance understanding of cognitive
trajectories after stroke. There is an opportunity to progress
by including cognitive tests in ongoing multicentre stroke
trials where feasible as pragmatic methods are becoming
available.3.2. Methods for assessing vascular effects on cognition
and neurodegeneration
Vascular disease requires different methods compared
with other types of neurodegeneration or dementia research.
Two keymethods, which differ substantially in their require-
ments for vascular disease and neurodegenerative pathol-
ogies such as AD, are the assessment of neuroimaging and
cognition. Integrated cerebrovascular disease codes are
essential to bridge clinical presentations. All are discussed
here.
3.2.1. Imaging, protocols, and analysis methods
In the 1990s, landmark neuroepidemiological studies
showed that clinically silent cerebrovascular lesions de-
tected only on MRI, including lacunes and WMH of pre-
sumed vascular origin, were associated with cognitive
impairment and an increased risk of future stroke and
Fig. 3. Dynamic effects of small vessel disease on the brain: (A) Periven-
tricular and deep white matter hyperintensity (WMH; orange) can increase
in size (red), occasionally shrink, and lead to atrophy of white matter. (B)
Acute small subcortical infarcts (dashed black line) may cavitate and shrink
(black area), develop into a WMH (orange) or disappear. Distant effects
(blue) involve thinning of connected cortex and degeneration of projection
fibers.
METACOHORTS Consortium / Alzheimer’s & Dementia 12 (2016) 1235-12491242dementia [41,42]. More recent studies have incorporated
advanced imaging modalities that interrogate physiological
and molecular changes—such as structural and functional
connectivity with diffusion tensor imaging and functional
MRI, cerebral perfusion, and molecular markers such as
amyloid deposition—with larger sample sizes to increase
statistical power for subgroup analyses and to predict
clinical events.
Our synthesis of cohort studies identified many partici-
pants in community-dwelling settings and clinical studies
on stroke who have cognitive data and undergone or will un-
dergo neuroimaging, predominantly brain MRI (Table 1,
Supplementary Table 1). We identified five major areas
where there are currently limitations, gaps in knowledge,
or unrealized opportunities for harmonization and collabora-
tion of neuroimaging methods.
First, vascular lesion definitions and terminology require
standardization, to enable cross-cohort comparisons and
meta-analysis. This need has largely been met by the recent
STandards for ReportIng Vascular ChangEs Neuroimaging
(STRIVE) [44]; however, updates will become necessary
for new neuroimaging methods that bring new imaging
markers or increased sensitivity of known markers.
Second, to harmonize and compare findings across
studies, full details of neuroimaging acquisition and analysis
methods should be reported. New studies could adopt suc-
cessful, validated methods recommended by STandards for
ReportIng Vascular ChangEs Neuroimaging or used previ-
ously if the full methodological details were available. Imag-
ing protocols could be shared through a single, publicly
available website.
Third, reliability and accuracy of lesion classification
would be improved through sharing of (exemplary) MRI
data across cohorts with appropriate anonymization. For vi-
sual rating, a shared MRI repository could be used to train
new raters using expert consensus as the gold standard.
For computational analysis, for example, of MRI WMH, a
repository could allow developers access to MRI images
showing a range of lesions, from different vendors and field
strengths, to derive or validate processing methods.
Fourth, there is great need for integrating information on
vascular and neurodegenerative pathology from cohorts re-
cruited through different settings, leveraging the expertise
of stroke and dementia specialists in vascular and neurode-
generative disease. Integrating data across geographic and
race/ethnic backgrounds would also help to more reliably
identify and explore differences in subclinical vascular brain
injury.
Fifth, more collaboration would enhance innovative
methods for neuroimaging post-processing and data anal-
ysis. One example is the increasing emphasis on integrated
data analysis to determine total SVD burden and effects on
brain connectivity, neurodegeneration, and cognition
(Fig. 3). Advances in machine learning and graph theory–
based network analysis provide new opportunities to accel-
erate image analysis for large-scale studies. A multidisci-plinary approach including neuroepidemiologists and
clinical researchers on the one hand, and computer scien-
tists, mathematicians and biomedical engineers on the other
hand, is required.3.2.2. Cognition
There are particular challenges in the assessment of
cognition in patients with cerebrovascular diseases,
rendering detailed neuropsychological approaches (typi-
cally used in studies of dementia) impractical. Fatigue is
common after stroke, limiting patient tolerance of prolonged
tests. Patients may have dysphasia, impaired hand function,
or visual deficits, making some tests impossible, even if
comprehension is preserved. Depression and apathy are
common in SVD and affect cognitive test performance.
Many brief cognitive screening tests focus on memory,
although vascular disease, in particular SVD, typically re-
sults in subcortical cognitive impairments, for example,
loss of frontal and executive function [7,43], and may
occur in a stepwise manner reflecting sudden vascular
events.
The survey shows huge variability in cognitive outcome
measures in stroke/TIA patients (Table 1, Supplementary
Material). About 25% of studies used a diagnosis of
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(most commonly MoCA, MMSE, or the revised Adden-
brooke’s cognitive examination); less than 10% assessed
the premorbid (i.e., optimal early adulthood) cognitive sta-
tus; and few assessed cognition immediately before the
stroke. Of cognitive domains assessed in these studies, there
was an almost equal distribution among memory, executive
functions, reaction time, visuospatial function, with many
accounting also for depression and anxiety.
Longitudinal observational studies included patients with
different cognitive impairment or dementia diagnoses, but of
note, about half the studies did not assign a specific dementia
type and the diagnostic criteria forMCI, AD, vascular cogni-
tive impairment (VCI), and dementia varied. The most
commonly used criteria were the National Institutes of Ag-
ing-Alzheimer’s Association for MCI and AD, Diagnostic
and Statistical Manual of Mental Disorders, IV Edition for
dementia, and the American Heart Association/American
Stroke Association for VCI. However, with the exception
of the widely used Diagnostic and Statistical Manual of
Mental Disorders, IV Edition criteria for dementia, most
studies used widely differing criteria for other categories
of cognitive disorders, perhaps reflecting the difficulties
and complexity of cognitive assessment in vascular disease.
Most community-based and longitudinal observational
studies used the MMSE, which is insensitive to vascular
cognitive decline. A stepwise approach to determining the
cognitive test approach to vascular disease is suggested in
Table 3.
The importance of assessing cognitive profiles (without
worsening the complexity of categorization) is emphasized
by recent findings in SVD patients of memory loss (a cortical
dysfunction) [7,44], suggesting that SVD affects not just
white and deep gray matter but also the (connected)
cerebral cortex (Fig. 3) [44–46]. Lower connectivity
within cerebral networks was associated with cognitive
impairment and dementia [47,48]; WMHs were associated
with less brain activation in the frontal cortex on
fludeoxyglucose-positron emission tomography [49–51].
Mood disorders and apathy are common after stroke,
affect cognitive test performance (and more
fundamentally, patient participation in research), and may
reflect impaired connectivity. Integrating the results from
different cohorts that investigate these underlying
mechanisms and consequences is essential to understandTable 3
Choosing tests to measure cognition in studies and trials dealing with
vascular diseases: a step-based process
1) Decide to assess cognition (mandatory)
2) Decide whether to assess
a) diagnostic outcome measure (e.g., dementia, cognitive decline,
mild cognitive impairment) and/or
b) cognitive measures (i.e., use domain-specific cognitive tests)
4) If b, decide which domains to assess, and
5) Which tests to use.the full impact of vascular disease on brain function and
progression toward the complete spectrum of cognitive
impairments.
3.2.3. Relevance and mapping to next generation disease
coding, ICD-11
Accurate and uniformly applied diagnoses are essential in
health care and research. TheWorld Health Organization has
the main responsibility for the global classification systems,
a core constitutional task. ICD-10 was published about
25 years ago. Major advances in the understanding of dis-
eases have occurred since then, making ICD-10 outdated
in several areas. The revision of ICD-10 into ICD-11 is
currently in its final stage.
A major change from ICD-10 to ICD-11 is that cerebro-
vascular diseases will no longer be split across different
chapters, but will constitute “one single section” inDiseases
of the Nervous System. ICD-11 will also, for the first time,
include definitions of all cerebrovascular diagnostic codes
including definitions of transient ischemic attack and the
different main types of stroke. It will also encompass cere-
brovascular diseases not causing acute neurological
dysfunction: silent cerebral infarcts, cerebral microbleeds,
and silent white matter abnormalities associated with
vascular disease. The term “silent” denotes that these en-
tities have not caused acute neurologic symptoms (and hence
are not “strokes”) but are important for brain function, affect
prognosis, and should not be regarded only as incidental im-
aging findings.
The final ICD-11 classification is expected to be approved
for governmental use by the World Health Assembly for
release in 2018, but the prefinal beta draft is officially avail-
able at the World Health Organization website [52]. For
several research purposes, it is recommended that the ICD-
11 terminology and definitions be considered and may be
applied already at this stage.4. Discussion
Our initiative identified more than 90 cohort studies,
including over 660,000 participants, many outside current
neurodegeneration data initiatives, most with consent for
data sharing, providing substantial scope for data mining.
We acknowledge that our survey is incomplete. However,
we consider it sufficiently representative to draw important
conclusions. The segregation of stroke and dementia re-
mains prevalent 10 years after the National Institute of
Neurological Disorders and Stroke-Canadian Stroke
Network (NINDS-CSN) standards [11], in spite of recogni-
tion that larger frameworks and better diagnostic criteria
for dementias are urgently needed [1,53]. Even among
the survey respondents (likely “cerebrovascular disease
enthusiasts”), there was a large gap between “stroke” and
“dementia,” and sparse overlap with the JPND report
[14]. Although stroke clinic–based studies and RCTs
were trying to collect at least some cognitive data, the
Table 4
Recommendations for research
Recommendation Reason 1 Reason 2 Reason 3
General Vascular and neurodegenerative
pathologies are closely related;
vascular pathology is an integral
part of the pathological spectrum
of AD, and vascular disease can
play an important primary or
secondary role to other pathology
in neurodegeneration and
dementia.
Secondary neurodegeneration due to
vascular insults is an important
contributor to accumulating
structural brain damage and brain
dysfunction.
Vascular damage can manifest as
progressive cognitive, behavioral
or sensorimotor dysfunction, that
is, not just stroke.
Integrated approaches are needed Vascular neurodegenerative disorders
may present to many different
clinics but are underpinned by a
common vascular disorder.
These clinics should integrate to
avoid overlooking the multifaceted
effects of vascular disease on
cognition, psychiatric symptoms,
and physical function.
Clinical practice and research should
assess risk factors, clinical,
cognitive, imaging, and physical
function.
Vascular disease is a dynamic and
far-reaching process
Apparently small lesions that may
precipitate clinical presentations
have remote effects on other parts
of the brain, which increase
neurological and cognitive
dysfunction.
Small lesions are also evidence of a
global brain disease and should be
treated as a progressive, global
pathology.
Vascular lesions are not small,
individually trivial lesions, without
clinical meaningfulness.
Always assess vascular risk factors,
disease burden, and outcomes
Cerebrovascular disease and AD
share multiple risk factors, for
example, smoking, hypertension,
hyperglycemia, diabetes, and
obesity. Vascular risk factors may
have a greater impact in midlife
than old age.
As an absolute minimum, routinely
assess history of cerebrovascular,
peripheral vascular, cardiovascular
disease, blood pressure, smoking,
exercise, occupation, and diet,
blood lipids, blood glucose.
Pragmatic approaches can be suitable
and avoid overburdening
researchers and participants.
Follow-up should continue long
term.
Cognitive assessments should be
performed in, and relevant to,
vascular disease
Need to be applicable to vascular
patients and the environment in
which they typically present.
Adapted to reflect their specific
cognitive deficits and physical
limitations.
Assess executive function and
processing speed in addition to
memory.
To avoid mistaking lifelong stable
traits for late life change, routinely
assess prior cognitive ability (or
proxy measures, e.g., educational
attainment) in any studies of
cognition and vascular disease or
other dementias.
Long-term outcome events, rates, and
timings of decline in cognitive and
physical function are needed to
power clinical trials and inform
patients and health services more
effectively.
Socioeconomic factors have major
influence on vascular disease
beyond that attributed to vascular
risk factors alone and should be
assessed routinely.
Assess physical function across
several domains routinely
Gait, balance, and continence are
often affected and should be
assessed routinely in suspected
vascular cognitive impairment.
Simple tests such as “timed up and
go” are valuable to assess physical
function.
Use standard, validated data
collection that accounts for
vascular disease
Agreed core standard data (clinical,
cognitive, imaging, biomarkers,
and so forth) and definitions would
facilitate future data sharing and
meta-analyses.
Agreed standards are available, for
example, NINDS-CSN Vascular
Cognitive Impairment
Harmonization Standards; or
STRIVE standards for
neuroimaging.
Imaging can identify “silent” and
symptomatic vascular disease if
the right sequences are used.
Encourage postmortem brain tissue
collection
Brain tissue from subjects well
phenotyped in life, including brain
regions commonly affected by
vascular disease, are not widely
available; storing samples frozen,
and in paraffin, would facilitate
protein, and gene as well as
histological assessments.
More research is needed on the
interaction of AD with
cerebrovascular pathology, the
consequences for function of brain
networks, and ultimately how
these pathologies evolve and
combine to cause clinical
consequences.
Tissue-imaging analysis of individual
lesions is needed to understand
pathological mechanisms.
Make better use of existing cohort
data
Study registration and public
availability of protocols would
facilitate identification of novel
and ongoing studies for meta-
analyses.
Cohorts that assess cerebrovascular
disease and include molecular
imaging to assess AD pathology
(e.g., by PET amyloid imaging)
will help understand joint
pathologies.
Open data initiatives and databanks
would encourage sharing of
existing cohort data.
Abbreviations: AD, Alzheimer’s disease; PET, positron emission tomography.
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optimal. Meanwhile, the memory clinic–based cohorts
collected relatively little information on vascular disease.
Undoubtedly, the role of vascular disease in neurodegener-
ation remains under-recognized, and under-funded [54], a
situation that can no longer be justified: vascular risk factor
reduction prevents stroke and may also prevent dementia
[3] further evidenced by declining dementia incidence par-
alleling declining stroke incidence [16]. Fortunately, per-
spectives may be evolving. A recent call for new
conceptual formulations of AD and dementia cites the
need to account for mixed pathologies and known risk fac-
tors (many of which are also stroke risk factors) [55].
Furthermore, ICD-11 should help identify all cerebrovas-
cular disease presentations. Standardized diagnostic
workup and data collection would facilitate studies on diag-
nosis, prognosis, and treatment of vascular factors in a
memory clinic setting, and similarly, studies of cognition,
gait, and balance in a stroke clinic setting (Table 4). “Trans-
nosological” research units, integrating specialists in neu-
rovascular and neurodegenerative disorders would
facilitate a global approach to dementia prevention.
These survey data provide a framework for addressing in-
teractions between the two leading causes of cognitive
decline and dementia: vascular disease and neurodegenera-
tion. Epidemiological studies and RCTs are highly comple-
mentary when viewed as large data sets en masse.
Observational studies indicate that the most critical period
for elevated blood pressure with regard to cognitive decline
is midlife, whereas blood pressure–lowering trials mostly
included older patients with follow-up periods too short to
detect an effect. Population studies inform hospital-based
post-stroke dementia studies (and vice versa), often have
repeated measures gathered over many years, enabling the
impact of cumulative exposures, and of exposure during spe-
cific ages, to be explored. Important early life information is
present in these studies, for example, birth weight, childhood
cognition, socioeconomic data, for subjects now aged 50 to
70 years, enabling assessment of early life factors on cere-
brovascular disease and dementia risk. Capturing informa-
tion on both vascular and neurodegenerative disease from
mixed sources improves generalizability (e.g., RUN DMC;
FUTURE; Lund Stroke Registry, Supplementary Table 1).
Combining studies that focus on populations in different
epidemiological “windows” relative to the expression of dis-
ease enhances mechanisms’ discovery and can relate sys-
temic disease risk (obesity, metabolic, and cardiovascular
disease) to cerebrovascular disease and dementia. Cohort
meta-analyses would help clarify long-term event rates, their
prediction, risk factors, and variation between populations
and improve design of RCTs. Existing studies may provide
well-phenotyped “trial ready” subjects with prospective con-
sent for future research. The challenges involved in harmo-
nization and analysis of large, diverse data sets are
substantial (Table 4), but methods to overcome this are
ongoing [56], and the potential rewards are huge. Workalready ongoing as a result of this initiative is listed in
Supplementary Table 2.
Agreeing on a unified cognitive assessment, which can
be applied easily in cerebrovascular disease, is sensitive
to relevant domains and relevant to patients, could have
as much impact on identifying treatment to prevent VCI
as the Rankin Scale [57] has had on finding acute stroke
treatments: without the common language for functional
outcome provided by the Rankin scale, it is arguable that
stroke units, thrombolysis, hemicraniectomy, and throm-
bectomy would not have become guideline acute stroke in-
terventions in as little as 20 years. Currently, most stroke
RCTs, with few exceptions [58], do not assess cognition.
The evaluation of cognition in stroke patients is complex,
difficult, with no “best cognitive test”. The 2006 collabora-
tive consensus [11] proposed three cognitive protocols with
different lengths, one being a brief test for use in large
observational studies and RCTs. Pragmatic, rapid, vali-
dated, tools sensitive to cognitive domains affected by
vascular disease early on, are required, like the MoCA
[59]. Online cognitive tests, for example, the UK Biobank
Cognitive Testing Enhancement, are too complex for
many stroke patients. In any case, a stepwise approach is
needed to assess vascular effects on neurodegeneration
(Table 3). Simple, sensitive, cognitive scales for use in tele-
phone interviews, validated in patients with cerebrovascu-
lar disease, are needed (Table 4) [60].
Several large national initiatives will address dementia
prevention in line with the 2013 G8 Dementia Summit.
These draw largely on healthy or presymptomatic disease
populations and offer new opportunities for systematic,
prospective evaluations of people at scale, and often long-
term sample biobanking, genetics, and imaging, enabling
some powerful study designs. These include the Rhineland
study (Germany, DZNE, n5 40,000), the Canadian Longi-
tudinal Study on Aging (50,000 individuals), the Canadian
Alliance for Healthy Hearts and Minds and Prospective Ur-
ban Rural Epidemiological MIND (PURE-MIND, 11,200
persons), and the UK Biobank [61] (500,000 people aged
40–70, 100,000 with detailed imaging). These long-term
initiatives are complemented by several national and
regional efforts to establish disease-based cohorts, for
example, the Canadian Consortium on Neurodegeneration
in Aging (1400 persons; AD, mixed dementia, MCI, and
VCI), or to combine existing cohorts, for example, the
DPUK [62], (29 UK community cohorts), Cohort Studies
of Memory in an International Consortium (COSMIC)
[18], Virtual International Stroke Trials Archive (VISTA)
Cognition [22], and STROKOG [23]. Other regions should
be encouraged and are creating large repositories of data—
Asia Pacific Region, Central and America [63], Russia, Af-
rica [64], and Australasia [18].
Governments, funders, and the public recognize the
importance of sharing publicly funded data. Data from
combined analyses of cohorts would provide larger sam-
ples, more robust data on individual cognitive and physical
METACOHORTS Consortium / Alzheimer’s & Dementia 12 (2016) 1235-12491246outcomes, and the interplay between brain and body to
maintain healthy, active populations into old age. The
2015 World Stroke Proclamation on preventable dementias
[1] has been endorsed by several international Alzheimer’s,
neurological, psychiatric, and heart associations. Funding
for cerebrovascular disease research should more closely
match that spent on dementia or cardiac disease [54]. Re-
searchers should work together to operationalize assess-
ment of vascular effects on neurodegeneration; stroke
should move from “stroke-related” to “anything vascular
related including cognition or other effects” [52]; and de-
mentia should move from AD to “any disorder, arising in
or outside the brain, that progressively diminishes cognitive
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